The Office of Pharmaceutical Quality (OPQ) under the U.S. Food and Drug Administration (FDA) has issued a new report that gives insights into the agency's quality of drugs and biologics that are provisioned for the U.S. market. The report comes afresh looking after the recent drug quality in the country.

According to the FDA's report, there has been an 8.6% decrease in the number of drug manufacturing sites in its catalog—4,676 in FY2018 to 4,273. This is after adding 382 new manufacturing sites. FDA acknowledges the drop in manufacturing sites with over the counter drugs and homeopathic drugs as the reason for the decrease this year. It also further notes a decrease in the sites that only perform operations in packaging and labeling.